About the Company
We do not have any company description for Aligos Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Aligos Therapeutics, Inc.
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
Aligos Therapeutics, Inc. (ALGS) closed the last trading session at $8.77, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs
Aligos Therapeutics (ALGS) announced the appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs, effective ...
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics, Inc. (Nasdaq: ALGS, 'Aligos”, 'Company”), a clinical stage biopharmaceutical company focused on ...
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the ...
Aligos Therapeutics Inc. R (5WK0.DU) - Yahoo Finance
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through ...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter ...
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases.
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue ...
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.
Aligos Therapeutics Inc. Presents Positive Clinical Data from ALG ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today ...
Aligos Therapeutics Reports Recent Business Progress and Third Quarter ...
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases.
Similar Companies
Loading the latest forecasts...